1182-Low dose cytarabine | eviQ
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi - The Lancet Haematology
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome - ScienceDirect
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy | Journal of Hematology & Oncology | Full Text
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Prevention and Treatment of Cytarabine-Induced Keratoconjunctivitis
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE SC Regimen • Acute Myeloid Leukaemia – Cytarabine SC Indication •
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low -dose cytarabine and placebo in older adults with untreated acute myeloid leukemia | Haematologica
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients - ScienceDirect
352-Consolidation HiDAC (cytarabine) 1,3,5 | eviQ
Approved for use in:
Acute myeloid leukemia—Major progress over four decades and glimpses into the future - Kantarjian - 2016 - American Journal of Hematology - Wiley Online Library
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
HIVH AML-88 Protocol. | Download Table
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial - The Lancet Haematology
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves
Frontiers | Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia - ScienceDirect
